Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency

A randomized double-blind trial

Chaim M. Roifman, Harry Schroeder, Melvin Berger, Ricardo Sorensen, Mark Ballow, Rebecca H. Buckley, Anita Gewurz, Phillip Korenblat, Gordon Sussman, Georg Lemm, Mark Stein, Donald Stark, Maria Louisa Ermitano, Anne Desroches, Bruce Mazer, Joseph Church, Zuhair Ballas, Alexandra Filipovich, Gilbert Friday, Donatella Graffino & 7 others Melvin Haysman, Alan Knutsen, Wendel Richmond, Arye Rubinstein, Frederick Marquinez, Don McNeil, Susanne Skoda-Smith

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

A novel method of large-scale chromatography has been developed to improve recovery and purity of immunoglobulin G (IgG) from pooled plasma. The current study compares safety, toxicity and efficacy of two intravenous immunoglobulin products: a novel formulation, IGIV caprylate/chromatography (IGIV-C; Gamunex™, 10%) and a licensed solvent/detergent-treated product, Gamimune®N, 10% (IGIV-SD). The study, a randomized, double-blind, parallel group, therapeutic equivalence trial, was conducted at 25 treatment centers in Canada and the United States. Patients (n=172) having confirmed chronic primary immunodeficiency (PID), aged 1-75 years, and receiving IGIV therapy were enrolled. For 9 months, patients were treated with IGIV-C or IGIV-SD in accordance with the patient's individualized treatment regimen utilized before study entry. The primary endpoint was the proportion of patients with ≥1 validated acute sinopulmonary infection during the treatment period. Secondary endpoints included the proportion of patients with all infections, time to first infection, annual infection rates, lung function parameters, infusion-related safety and viral safety. The annual validated infection rate in the IGIV-C group was 0.18 compared to 0.43 in the IGIV-SD group (p=0.023). Nine patients receiving IGIV-C experienced validated infections, compared to 17 patients in IGIV-SD group (p=0.06). Acute sinusitis (validated plus clinically defined) was less frequent in the IGIV-C group (p=0.012). Presence of bronchiectasis did not affect efficacy. Adverse reactions were similar in frequency and severity in both groups. No evidence of viral transmission was observed. IGIV-C appears to be superior to IGIV-SD in preventing validated sinopulmonary infections, especially acute sinusitis, in patients with PID.

Original languageEnglish (US)
Pages (from-to)1325-1333
Number of pages9
JournalInternational Immunopharmacology
Volume3
Issue number9
DOIs
StatePublished - Sep 2003

Fingerprint

Caprylates
Chromatography
Infection
Intravenous Immunoglobulins
Sinusitis
Therapeutics
Safety
Bronchiectasis
Detergents
Canada
Immunoglobulin G
Lung

Keywords

  • IgG
  • IGIV
  • Immunoglobulin
  • Immunotherapy
  • IVIG
  • Primary immunodeficiency
  • Sinopulmonary infection
  • Sinusitis
  • Viral safety

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency : A randomized double-blind trial. / Roifman, Chaim M.; Schroeder, Harry; Berger, Melvin; Sorensen, Ricardo; Ballow, Mark; Buckley, Rebecca H.; Gewurz, Anita; Korenblat, Phillip; Sussman, Gordon; Lemm, Georg; Stein, Mark; Stark, Donald; Ermitano, Maria Louisa; Desroches, Anne; Mazer, Bruce; Church, Joseph; Ballas, Zuhair; Filipovich, Alexandra; Friday, Gilbert; Graffino, Donatella; Haysman, Melvin; Knutsen, Alan; Richmond, Wendel; Rubinstein, Arye; Marquinez, Frederick; McNeil, Don; Skoda-Smith, Susanne.

In: International Immunopharmacology, Vol. 3, No. 9, 09.2003, p. 1325-1333.

Research output: Contribution to journalArticle

Roifman, CM, Schroeder, H, Berger, M, Sorensen, R, Ballow, M, Buckley, RH, Gewurz, A, Korenblat, P, Sussman, G, Lemm, G, Stein, M, Stark, D, Ermitano, ML, Desroches, A, Mazer, B, Church, J, Ballas, Z, Filipovich, A, Friday, G, Graffino, D, Haysman, M, Knutsen, A, Richmond, W, Rubinstein, A, Marquinez, F, McNeil, D & Skoda-Smith, S 2003, 'Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: A randomized double-blind trial', International Immunopharmacology, vol. 3, no. 9, pp. 1325-1333. https://doi.org/10.1016/S1567-5769(03)00134-6
Roifman, Chaim M. ; Schroeder, Harry ; Berger, Melvin ; Sorensen, Ricardo ; Ballow, Mark ; Buckley, Rebecca H. ; Gewurz, Anita ; Korenblat, Phillip ; Sussman, Gordon ; Lemm, Georg ; Stein, Mark ; Stark, Donald ; Ermitano, Maria Louisa ; Desroches, Anne ; Mazer, Bruce ; Church, Joseph ; Ballas, Zuhair ; Filipovich, Alexandra ; Friday, Gilbert ; Graffino, Donatella ; Haysman, Melvin ; Knutsen, Alan ; Richmond, Wendel ; Rubinstein, Arye ; Marquinez, Frederick ; McNeil, Don ; Skoda-Smith, Susanne. / Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency : A randomized double-blind trial. In: International Immunopharmacology. 2003 ; Vol. 3, No. 9. pp. 1325-1333.
@article{abdea38a90ee4423904f6ac7ca956321,
title = "Comparison of the efficacy of IGIV-C, 10{\%} (caprylate/chromatography) and IGIV-SD, 10{\%} as replacement therapy in primary immune deficiency: A randomized double-blind trial",
abstract = "A novel method of large-scale chromatography has been developed to improve recovery and purity of immunoglobulin G (IgG) from pooled plasma. The current study compares safety, toxicity and efficacy of two intravenous immunoglobulin products: a novel formulation, IGIV caprylate/chromatography (IGIV-C; Gamunex™, 10{\%}) and a licensed solvent/detergent-treated product, Gamimune{\circledR}N, 10{\%} (IGIV-SD). The study, a randomized, double-blind, parallel group, therapeutic equivalence trial, was conducted at 25 treatment centers in Canada and the United States. Patients (n=172) having confirmed chronic primary immunodeficiency (PID), aged 1-75 years, and receiving IGIV therapy were enrolled. For 9 months, patients were treated with IGIV-C or IGIV-SD in accordance with the patient's individualized treatment regimen utilized before study entry. The primary endpoint was the proportion of patients with ≥1 validated acute sinopulmonary infection during the treatment period. Secondary endpoints included the proportion of patients with all infections, time to first infection, annual infection rates, lung function parameters, infusion-related safety and viral safety. The annual validated infection rate in the IGIV-C group was 0.18 compared to 0.43 in the IGIV-SD group (p=0.023). Nine patients receiving IGIV-C experienced validated infections, compared to 17 patients in IGIV-SD group (p=0.06). Acute sinusitis (validated plus clinically defined) was less frequent in the IGIV-C group (p=0.012). Presence of bronchiectasis did not affect efficacy. Adverse reactions were similar in frequency and severity in both groups. No evidence of viral transmission was observed. IGIV-C appears to be superior to IGIV-SD in preventing validated sinopulmonary infections, especially acute sinusitis, in patients with PID.",
keywords = "IgG, IGIV, Immunoglobulin, Immunotherapy, IVIG, Primary immunodeficiency, Sinopulmonary infection, Sinusitis, Viral safety",
author = "Roifman, {Chaim M.} and Harry Schroeder and Melvin Berger and Ricardo Sorensen and Mark Ballow and Buckley, {Rebecca H.} and Anita Gewurz and Phillip Korenblat and Gordon Sussman and Georg Lemm and Mark Stein and Donald Stark and Ermitano, {Maria Louisa} and Anne Desroches and Bruce Mazer and Joseph Church and Zuhair Ballas and Alexandra Filipovich and Gilbert Friday and Donatella Graffino and Melvin Haysman and Alan Knutsen and Wendel Richmond and Arye Rubinstein and Frederick Marquinez and Don McNeil and Susanne Skoda-Smith",
year = "2003",
month = "9",
doi = "10.1016/S1567-5769(03)00134-6",
language = "English (US)",
volume = "3",
pages = "1325--1333",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency

T2 - A randomized double-blind trial

AU - Roifman, Chaim M.

AU - Schroeder, Harry

AU - Berger, Melvin

AU - Sorensen, Ricardo

AU - Ballow, Mark

AU - Buckley, Rebecca H.

AU - Gewurz, Anita

AU - Korenblat, Phillip

AU - Sussman, Gordon

AU - Lemm, Georg

AU - Stein, Mark

AU - Stark, Donald

AU - Ermitano, Maria Louisa

AU - Desroches, Anne

AU - Mazer, Bruce

AU - Church, Joseph

AU - Ballas, Zuhair

AU - Filipovich, Alexandra

AU - Friday, Gilbert

AU - Graffino, Donatella

AU - Haysman, Melvin

AU - Knutsen, Alan

AU - Richmond, Wendel

AU - Rubinstein, Arye

AU - Marquinez, Frederick

AU - McNeil, Don

AU - Skoda-Smith, Susanne

PY - 2003/9

Y1 - 2003/9

N2 - A novel method of large-scale chromatography has been developed to improve recovery and purity of immunoglobulin G (IgG) from pooled plasma. The current study compares safety, toxicity and efficacy of two intravenous immunoglobulin products: a novel formulation, IGIV caprylate/chromatography (IGIV-C; Gamunex™, 10%) and a licensed solvent/detergent-treated product, Gamimune®N, 10% (IGIV-SD). The study, a randomized, double-blind, parallel group, therapeutic equivalence trial, was conducted at 25 treatment centers in Canada and the United States. Patients (n=172) having confirmed chronic primary immunodeficiency (PID), aged 1-75 years, and receiving IGIV therapy were enrolled. For 9 months, patients were treated with IGIV-C or IGIV-SD in accordance with the patient's individualized treatment regimen utilized before study entry. The primary endpoint was the proportion of patients with ≥1 validated acute sinopulmonary infection during the treatment period. Secondary endpoints included the proportion of patients with all infections, time to first infection, annual infection rates, lung function parameters, infusion-related safety and viral safety. The annual validated infection rate in the IGIV-C group was 0.18 compared to 0.43 in the IGIV-SD group (p=0.023). Nine patients receiving IGIV-C experienced validated infections, compared to 17 patients in IGIV-SD group (p=0.06). Acute sinusitis (validated plus clinically defined) was less frequent in the IGIV-C group (p=0.012). Presence of bronchiectasis did not affect efficacy. Adverse reactions were similar in frequency and severity in both groups. No evidence of viral transmission was observed. IGIV-C appears to be superior to IGIV-SD in preventing validated sinopulmonary infections, especially acute sinusitis, in patients with PID.

AB - A novel method of large-scale chromatography has been developed to improve recovery and purity of immunoglobulin G (IgG) from pooled plasma. The current study compares safety, toxicity and efficacy of two intravenous immunoglobulin products: a novel formulation, IGIV caprylate/chromatography (IGIV-C; Gamunex™, 10%) and a licensed solvent/detergent-treated product, Gamimune®N, 10% (IGIV-SD). The study, a randomized, double-blind, parallel group, therapeutic equivalence trial, was conducted at 25 treatment centers in Canada and the United States. Patients (n=172) having confirmed chronic primary immunodeficiency (PID), aged 1-75 years, and receiving IGIV therapy were enrolled. For 9 months, patients were treated with IGIV-C or IGIV-SD in accordance with the patient's individualized treatment regimen utilized before study entry. The primary endpoint was the proportion of patients with ≥1 validated acute sinopulmonary infection during the treatment period. Secondary endpoints included the proportion of patients with all infections, time to first infection, annual infection rates, lung function parameters, infusion-related safety and viral safety. The annual validated infection rate in the IGIV-C group was 0.18 compared to 0.43 in the IGIV-SD group (p=0.023). Nine patients receiving IGIV-C experienced validated infections, compared to 17 patients in IGIV-SD group (p=0.06). Acute sinusitis (validated plus clinically defined) was less frequent in the IGIV-C group (p=0.012). Presence of bronchiectasis did not affect efficacy. Adverse reactions were similar in frequency and severity in both groups. No evidence of viral transmission was observed. IGIV-C appears to be superior to IGIV-SD in preventing validated sinopulmonary infections, especially acute sinusitis, in patients with PID.

KW - IgG

KW - IGIV

KW - Immunoglobulin

KW - Immunotherapy

KW - IVIG

KW - Primary immunodeficiency

KW - Sinopulmonary infection

KW - Sinusitis

KW - Viral safety

UR - http://www.scopus.com/inward/record.url?scp=10744229712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229712&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(03)00134-6

DO - 10.1016/S1567-5769(03)00134-6

M3 - Article

VL - 3

SP - 1325

EP - 1333

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 9

ER -